(19)
(11) EP 4 153 587 A1

(12)

(43) Date of publication:
29.03.2023 Bulletin 2023/13

(21) Application number: 21809570.1

(22) Date of filing: 18.05.2021
(51) International Patent Classification (IPC): 
C07D 417/14(2006.01)
A61P 35/00(2006.01)
C07D 413/04(2006.01)
A61K 47/50(2017.01)
 C07D 417/04(2006.01)
C07D 413/02(2006.01)
C07D 401/04(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07D 417/14; C07D 417/12; A61K 47/55; A61K 47/545
(86) International application number:
PCT/US2021/033039
(87) International publication number:
WO 2021/236695 (25.11.2021 Gazette 2021/47)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 18.05.2020 US 202063026449 P
10.07.2020 US 202063050735 P
03.05.2021 US 202163183371 P

(71) Applicant: Montelino Therapeutics, Inc.
Southborough MA 01772 (US)

(72) Inventors:
  • DESANTIS, Jenny
    06034 Foligno (IT)
  • VAZ, Roy Joseph
    Southborough, Massachusetts 01772 (US)
  • ELEUTERI, Michela
    06036 Montefalco (IT)

(74) Representative: Pharma Patents International AG 
Leonhardsgraben 52
4051 Basel
4051 Basel (CH)

   


(54) BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR